Developments and Challenges for mAb-Based Therapeutics
Open accessThe DOI matches its Crossref record; 311 of the 323 references it cites were found in a registry or an index.
Abstract
The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Illustration of various bispecific antibodies, including bispecific T-cell engager (BiTE®), Dual-Affinity Re-Targeting (DART TM ), tetravalent bispecific recombinant antibody (TandAb®), and Immune mobilizing mTCR Against Cancer (ImmTAC). Figure from May et al . [225].](https://figures.cochat.ai/paper-figures/5d310da2be2444458c77c065c03ebb84/developments-and-challenges-for-mab-based-therapeutics-figure-5.png)
![Figure 6 Schematic representation of various antibody formats, including the intact IgG molecule alongside various representations of antibody fragments. Figure from Holliger and Hudson [273].](https://figures.cochat.ai/paper-figures/47722ba8bb914780bc001d2282910ed1/developments-and-challenges-for-mab-based-therapeutics-figure-6.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PAT enables measurement of physical instabilities such as aggregation or chemical alterations including post-translational modifications or cross-linking which can complement stabilization formulation strategies [92].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229 · cited 1×
“The development of hybridoma technology has enabled a consistent production of mAbs at large scale, paving the way for development of various therapeutic antibodies [4].”
BackgroundCoiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574 · cited 2×
“This drug is currently being utilized as a single agent (for induction and maintenance), or in combination with chemotherapeutic agents, for the treatment of various human lymphoma and chronic lymphocytic lymphoma [10,28].”
BackgroundInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“According to this mechanism, the Fc portion interacts with FCγ-receptors on the surface of the effector immune cells (such as monocyte and macrophages), while the antibody is bound to the surface antigen of the cancer cell through its Fab region, and results in ADCC response [21,22].”
BackgroundMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755 · cited 1×
“1997 Rituximab Rituxan® CD20 Non-Hodgkin’s lymphoma Chimeric IgG1 First approved full length chimeric mAb [10,11]”
BackgroundPhage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423 · cited 1×
“Another effective way of producing human antibody is phage display [20].”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“For example, bevacizumab binds to the soluble vascular endothelial growth factor (VEGF), and thus inhibits angiogenesis, which is important for the maintenance of tumor vasculature and tumor health [24].”
BackgroundScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Zhou, H.-X., Rivas, G., & Minton, A. P. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125817 · Cited by 2,149 · cited 1×
“[110,127].”
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931 · cited 1×
“and Hudson [273].”
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 1×
“Similarly, anti-angeogenic vascular endothelial growth factor (VEGF) inhibitor has been developed as an Fc-fusion protein, termed VEGF-Trap [220].”
Background
Research works printed but not linked: 4
- Pearlman, R., and Wang, Y.J. (1996). Formulation, Characterization, and Stability of Protein Drugs, Plenum Press.
- Hershenson, F.J.S. (2010). Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, John Wiley & Sons, Inc.
- Scherer, T., Kanai, S., Liu, J., and Shire, S. (, 2007). Characterization of monoclonal antibodies at high concentrations by light scattering. Proceedings of AAPS National Biotechnology Conference, San Diego, CA, USA.
- Brock, T.D. (1998). Milestones in Microbiology; 1556–1940, ASM Press.
Cited by
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola, M., Sequeira, J., Seiça, R., Veiga, F., Serra, J., Santos, A. C., & Ribeiro, A. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.001 · Cited by 234
Tomar, D. S., Kumar, S., Singh, S. K., Goswami, S., & Li, L. (2016) · mAbs · doi:10.1080/19420862.2015.1128606 · Cited by 214
“During downstream ultrafiltration and diafiltration steps, high viscosity of the antibody solution may increase the back pressure of the pump and decrease the transmembrane flux, which may increase the processing time, destabilize the drug substance and increase manufacturing costs.(14,15)”
BackgroundSelf-citationButreddy, A., Janga, K. Y., Ajjarapu, S., Sarabu, S., & Dudhipala, N. R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.188 · Cited by 171
Overview of Antibody Drug Delivery
Awwad, S., & Angkawinitwong, U. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030083 · Cited by 153
“High temperatures can lead to conformational destabilization or partial/complete unfolding [26] and a change in pH can lead to aggregation.”
BackgroundInfluentialThe role of Raman spectroscopy in biopharmaceuticals from development to manufacturing
Esmonde-White, K. A., Cuellar, M., & Lewis, I. R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03727-4 · Cited by 152
Metadata
- Authors
- Goswami, S., Wang, W., Arakawa, T., & Ohtake, S.
- Affiliations
- Pfizer (United States) (US)
- Alliance Protein Laboratories (United States) (US)
- Corresponding author
- Arakawa, Tsutomu
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2013-08-16
- Volume
- 2
- Issue
- 3
- Pages
- 452-500
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2033785641
- Cited by
- 144
- References
- 323
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 10 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 18 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 12 · 2015: 10 · 2014: 4 · 2013: 1
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- monoclonal antibodies, biologic therapy, antibody-drug conjugates, bispecific antibodies, fusion protein, high-concentration formulations, antibody stabilization, antibody production
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developments and Challenges for mAb-Based Therapeutics. https://app.cochat.ai/papers/10.3390/antib2030452
- The paper
- Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013). Developments and Challenges for mAb-Based Therapeutics. Antibodies. https://doi.org/10.3390/antib2030452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.